Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers
16. November 2021 08:15 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
Company expands its management team to accelerate the commercialization and development of OT-101 for COVID-19
09. Juli 2020 07:00 ET
|
Mateon Therapeutics, Inc.
- Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics (MATN). Agoura Hills, California, July 09, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a late-stage...
Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine
07. Juli 2020 06:41 ET
|
Mateon Therapeutics, Inc.
Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19 Agoura Hills, California, July 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB:...